101 
Market Cap
Stock Chart
Circadian - 30 Day Poll
Recent BLOGS About Circadian Add New
Latest Company News
|
Morningstar places Speculative Buy rating on Circadian Technologies
Proactive Investors Australia - May 6, 2010 by Proactive Investors Australian stock market analysts, Morningstar Australia (incorporating Huntleys), recently released an analysis of Circadian Technologies (ASX:CIR) with a SPECULATIVE BUY ...
|
|
Circadian's VGX-100 inhibits tumour growth of cancer
Middle East North Africa Financial Network - Apr 19, 2010 (MENAFN Press) Data demonstrates efficacy of VGX-100 with other drugs in mouse models of prostate, pancreatic and brain cancers (glioblastoma). Treatment with VGX-100 plus anti-cancer drug Avastin ...
|
|
Circadian’s VGX-100 Significantly Inhibits Tumour Growth in Animal Models of Human Cancer
Business Wire - Apr 15, 2010 Data demonstrates efficacy of VGX-100 with other drugs in mouse models of prostate, pancreatic and brain cancers (glioblastoma). Treatment with VGX-100 plus anti-cancer drug Avastin and ...
Circadian Technologies' VGX-100 drug inhibits tumour growth - Proactive Investors AustraliaCIRCADIAN'S VGX-100 INHIBITS TUMOUR GROWTH IN ANIMAL MODELS - Trading Markets News-Medical.net |
|
Circadian Technologies Limited's VGX-100 Significantly Inhibits Tumour Growth In Animal Models Of Human Cancer
Reuters Key Development - Apr 15, 2010 |
|
Ms Natalie Korchev To Resign As CFO And Company Secretary Of Circadian Technologies Limited
Reuters Key Development - Apr 14, 2010 |
|
US Broker: "Circadian Technologies The Cheapest Little Antibody Company on the Planet"
Proactive Investors Australia - Mar 10, 2010 by Proactive Investors US-based investment bank Merriman Curhan Ford has issued a research report on local biotechnology company Circadian Technologies (ASX: CIR) with a BUY rating and a A$2.20-2 ...
US investment bank issues bullish note on Circadian Technologies - Proactive Investors USA & Canada |
|
Leading ASX Healthcare companies to present at "Ultimate Healthcare & Biotechnology Event 2010”
Proactive Investors Australia - Feb 24, 2010 by Proactive Investors Bionomics Ltd (ASX: BNO), Pulse Health Ltd (ASX: PHG), Circadian Technologies Ltd (ASX: CIR), Medical Australia Ltd (ASX: MLA), Stirling Products Ltd (ASX: STI) and CogState ...
|
|
Leading Healthcare & Biotechnology companies to present at "Ultimate Healthcare & Biotechnology Event 2010"
Proactive Investors Australia - Feb 17, 2010 by Proactive Investors The directors of Bionomics Limited (ASX: BNO), Pulse Health Limited (ASX: PHG), Circadian Technologies Limited (ASX: CIR), Medical Australia Limited (ASX: MLA), Stirling ...
|
Website
Videos related to Circadian
Company Profile
Cash reserves plus listed investments (at market value): on 30th June 2009 were $43.8 million
Possible events in next 12 months:
- VEGFR3 Abs IMC-3C5 for cancer (licensee ImClone) – IND filing sometime 2010
- CUP molecular diagnostic – Validation of test completed by Healthscope 2010 (a test for unkown primaries)
Overview:
Circadian has moved from being a biotechnology investor and incubator to a developer of angiogenesis-based therapeutics for cancer and other serious diseases. More specifically developing antibody therapies with an anti-angiogenic approach.
The portfolio covering key targets (Vascular Endothelial Growth Factors C and D) for the treatment of diseases associated with angiogenesis has been accumulated in Circadian’s unlisted subsidiary, Vegenics Limited. On August 14, 2008, Circadian announced that it had completed its acquisition of the Ludwig Institute for Cancer Research Ltd’s (LICR) and Licentia Limited’s (Licentia) combined 33% interest in Vegenics. This increased Circadian’s interest in Vegenics Limited from 67% to 100%
Has licensing deals with the following comapnies:
- ImClone Systems Inc (recently acquired by Eli Lilly & Co.- see USA sister website
- Healthscope Limited (ASX:HSP) developing cancer diagnostic test
People:
Of note the "Product Development Advisory Committee" has strong experience in international drug developmentand oncology.
– Errol Malta (Chair): ex Amgen
– George Morstyn: ex CMO Amgen
– Russell Howard: CEO Nasdaq listed Maxygen
– Ralph Smalling: ex Amgen Reg Affairs
– Richard Morgan: ex Glaxo-Wellcome
– Carlo Montagner: ex Aventis, Schering, Abraxis
Top 10 Sahreholders include institutional and professional investors:
- Packer and Co Limited 17.1
- Select Asset Management Ltd 8.1
- Ludwig Institute for Cancer Research 5.7
- Licentia Ltd 5.6
- Leon Serry 4.6
- HSBC Custody Nominees 2.7
- Chemical Trustee Limited 2.3
- Jagen Pty Ltd 2.2
- JFF Steven Pty Ltd 1.8
- Audivac Pty Ltd 1.7
Total 10 shareholders own 51.8%
Related comapnies or competition:
- Bionomics, see
http://www.bioinvest.com.au/company/Bionomics